Kay Robert 4/A

Accession 0001638599-19-000574

CIK 0001420720other

View on SEC.gov Company Profile

Filed

May 30, 8:00 PM ET

Accepted

May 31, 4:16 PM ET

Size

48.9 KB

Accession

0001638599-19-000574

Insider Transaction Report

Form 4/AAmended

Period: 2019-02-20

iBio, Inc.IBIO

KAY ROBERT

DirectorExecutive Chairman and CEO

Transactions

Disposition to Issuer
Stock Option (right to buy)
2019-02-20−25,000→ 307,500 total
Exercise: $6.60Exp: 2019-08-10→ Common Stock (25,000 underlying)
Award
Stock Option (right to buy)
2019-02-20+18,750→ 307,500 total
Exercise: $0.93Exp: 2024-02-20→ Common Stock (18,750 underlying)
Disposition to Issuer
Stock Option (right to buy)
2019-02-20−30,000→ 307,500 total
Exercise: $11.00Exp: 2022-07-24→ Common Stock (30,000 underlying)
Disposition to Issuer
Stock Option (right to buy)
2019-02-20−30,000→ 307,500 total
Exercise: $5.00Exp: 2023-07-16→ Common Stock (30,000 underlying)
Disposition to Issuer
Stock Option (right to buy)
2019-02-20−60,000→ 307,500 total
Exercise: $10.00Exp: 2024-09-05→ Common Stock (60,000 underlying)
Award
Stock Option (right to buy)
2019-02-20+22,500→ 307,500 total
Exercise: $0.93Exp: 2024-02-20→ Common Stock (22,500 underlying)
Award
Stock Option (right to buy)
2019-02-20+45,000→ 307,500 total
Exercise: $0.93Exp: 2024-02-20→ Common Stock (45,000 underlying)
Disposition to Issuer
Stock Option (right to buy)
2019-02-20−75,000→ 307,500 total
Exercise: $17.20Exp: 2025-09-04→ Common Stock (75,000 underlying)
Award
Stock Option (right to buy)
2019-02-20+56,250→ 307,500 total
Exercise: $0.93Exp: 2024-02-20→ Common Stock (56,250 underlying)
Disposition to Issuer
Stock Option (right to buy)
2019-02-20−30,000→ 307,500 total
Exercise: $4.00Exp: 2027-05-01→ Common Stock (30,000 underlying)
Disposition to Issuer
Stock Option (right to buy)
2019-02-20−30,000→ 307,500 total
Exercise: $17.30Exp: 2020-08-16→ Common Stock (30,000 underlying)
Award
Stock Option (right to buy)
2019-02-20+22,500→ 307,500 total
Exercise: $0.93Exp: 2024-02-20→ Common Stock (22,500 underlying)
Disposition to Issuer
Stock Option (right to buy)
2019-02-20−50,000→ 307,500 total
Exercise: $30.70Exp: 2020-12-30→ Common Stock (50,000 underlying)
Award
Stock Option (right to buy)
2019-02-20+37,500→ 307,500 total
Exercise: $0.93Exp: 2024-02-20→ Common Stock (37,500 underlying)
Disposition to Issuer
Stock Option (right to buy)
2019-02-20−50,000→ 307,500 total
Exercise: $30.70Exp: 2020-12-30→ Common Stock (50,000 underlying)
Award
Stock Option (right to buy)
2019-02-20+37,500→ 307,500 total
Exercise: $0.93Exp: 2024-02-20→ Common Stock (37,500 underlying)
Disposition to Issuer
Stock Option (right to buy)
2019-02-20−30,000→ 307,500 total
Exercise: $19.60Exp: 2021-10-21→ Common Stock (30,000 underlying)
Award
Stock Option (right to buy)
2019-02-20+22,500→ 307,500 total
Exercise: $0.93Exp: 2024-02-20→ Common Stock (22,500 underlying)
Award
Stock Option (right to buy)
2019-02-20+22,500→ 307,500 total
Exercise: $0.93Exp: 2024-02-20→ Common Stock (22,500 underlying)
Award
Stock Option (right to buy)
2019-02-20+22,500→ 307,500 total
Exercise: $0.93Exp: 2024-02-20→ Common Stock (22,500 underlying)

Footnotes (8)

[F1]Vested in five annual instalments on anniversaries of date of grant.
[F2]On 2/20/19, the issuer canceled, pursuant to the issuer's option exchange program, old stock options in exchange for new stock options, on the basis of three new options in exchange for four old options, for all eligible option holders who elected to participate in the option exchange, including the cancelation of this option grant to the reporting person in exchange for new options.
[F3]Reflects number of securities beneficially owned following all transactions reported on this Form 4/A.
[F4]Fully vests on first anniversary of grant date.
[F5]On 2/20/19, the issuer issued new stock options, pursuant to the issuer's option exchange program, in exchange for old stock options, on the basis of three new options in exchange for four old options, for all eligible option holders who elected to participate in the option exchange, including this option grant to the reporting person.
[F6]Vested 20% on 7/1/2010 and then in 20% instalments on each anniversary thereof.
[F7]Vested in three equal annual instalments on the anniversary of the date of grant.
[F8]This report on Form 4/A corrects an error with respect to the Amount of Securities Beneficially Owned Following Reported Transaction.

Documents

1 file

4
doc4a_6128.xml
PRIMARY DOCUMENT

Issuer

iBio, Inc.

CIK 0001420720

→

Entity typeother

Related Parties

filerCIK 0001285612

Filing Metadata

Form type: 4/A
Filed: May 30, 8:00 PM ET
Accepted: May 31, 4:16 PM ET
Size: 48.9 KB

View on SEC.gov